GSK : Q3 2023 infographic

Broad-based execution drives further sales and

Total sales

£8.1bn

+10%, +16%

including and excluding COVID-19 solutions

Vaccines

£3.2bn

+33%, +34%

including and excluding COVID-19 solutions

Specialty Medicines

£2.6bn

-1%, +17%

including and excluding COVID-19 solutions, with HIV +15%

earnings growth

"GSK is delivering strong and sustained performance momentum, with another quarter of double-digit sales and earnings growth. Competitive performance was broadly based but benefitted particularly from the outstanding US launch of Arexvy. Our excellent execution supports an upgrade to our full-year 2023 guidance and we have clear momentum as we look ahead to deliver our 2026 outlooks. GSK's longer-term outlook also continues

to strengthen, with progress in our vaccines pipeline, the development of our ultra long- acting HIV portfolio and significant new prospects in respiratory."

Emma Walmsley

Chief Executive Officer, GSK

		General Medicines
		£2.3bn
	-2%
Adjusted Group		Total EPS		Adjusted EPS
operating margin
34.0%		36.1p +>100%		50.4p +17%
Dividend	67	17
14p	vaccines and		pipeline assets
	specialty medicines		in phase III /
	in pipeline		registration

Journalists/media see press release on www.gsk.com for full details on Q3 2023.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 17-19, 51 and 52 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) ) and for continuing operations unless stated otherwise.

Ahead Together